A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study
Sill, M, Tenney, M.E, Darus, C.J, Griffin, D, Werner, T.L, Waggoner, S.E, Behrens, R.J
Published in Gynecologic oncology (01.04.2015)
Published in Gynecologic oncology (01.04.2015)
Get full text
Journal Article
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
Swain, S.M., Ewer, M.S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T.L., Douthwaite, H., Bradley, D., Waldron-Lynch, M., Kiermaier, A., Eng-Wong, J., Dang, C.
Published in Annals of oncology (01.03.2018)
Published in Annals of oncology (01.03.2018)
Get full text
Journal Article
Endometrial cancers are successfully targeted with a new pan-tyrosine kinase inhibitor in an orthotopic mouse model
Janát-Amsbury, M.M., Taurin, S., Yang, C.H., Reyes, M., Coombs, D., Jarboe, E.A., Werner, T.L., Peterson, C.M.
Published in Gynecologic oncology (01.06.2018)
Published in Gynecologic oncology (01.06.2018)
Get full text
Journal Article
LBA3 - VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
Coleman, R.L., Fleming, G.F., Brady, M.F., Swisher, E., Steffensen, K.D., Friedlander, M., Okamoto, A., Moore, K., Ben-Baruch, N., Werner, T.L., Oaknin, A., Nam, J.-H., Leath, C.A., Nicum, S., Cella, D., Sullivan, D.M., Ansell, P.J., Dinh, M., Aghajanian, C., Bookman, M.A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
Coleman, R.L., Fleming, G.F., Brady, M.F., Swisher, E., Steffensen, K.D., Friedlander, M., Okamoto, A., Moore, K., Ben-Baruch, N., Werner, T.L., Oaknin, A., Nam, J.-H., Leath, C.A., Nicum, S., Cella, D., Sullivan, D.M., Ansell, P.J., Dinh, M., Aghajanian, C., Bookman, M.A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)
Munster, P., van der Noll, R., Voest, E., Specht, J., Werner, T.L., Dees, E.C., Tan, A.R., Daud, A., Schellens, J., Lolkema, M.P., Griffin, M., Agarwal, N., Falchook, G.S., Kleha, J.F., Durante, M., Smith, D.A., Adams, L., Greshock, J., Morris, S.R., Kurzrock, R.
Published in Annals of oncology (01.09.2012)
Published in Annals of oncology (01.09.2012)
Get full text
Journal Article
442O - PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)
Munster, P., van der Noll, R., Voest, E., Specht, J., Werner, T.L., Dees, E.C., Tan, A.R., Daud, A., Schellens, J., Lolkema, M.P., Griffin, M., Agarwal, N., Falchook, G.S., Kleha, J.F., Durante, M., Smith, D.A., Adams, L., Greshock, J., Morris, S.R., Kurzrock, R.
Published in Annals of oncology (01.09.2012)
Published in Annals of oncology (01.09.2012)
Get full text
Journal Article